Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

moubarak1 2 posts  |  Last Activity: Apr 25, 2014 6:23 PM Member since: Feb 5, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Week of May 19th

    by moubarak1 Apr 25, 2014 1:27 PM
    moubarak1@gmail.com moubarak1 Apr 25, 2014 6:23 PM Flag

    The FDA is 2 weeks ahead schedule in my opinion.
    Examples include:
    Imbruvica, Alprolix, Afrezza, Dapagliflozin and the list goes on. All met 1-3 weeks early with the FDA in 2014.

    http://www.rttnews.com/corpinfo/fdacalendar.aspx

    We have a 25 day gap starting April 30th-March 25th where the FDA does not have any meetings scheduled.(catch-up if needed) Plus there are a lot less drugs up for review this part of the year compared to earlier in the year. So, if the companies listed above were able to meet early with the FDA during their busy season, I just cannot see why Keryx wont be 2 weeks ahead schedule.

    Sentiment: Strong Buy

  • moubarak1@gmail.com by moubarak1 Apr 25, 2014 1:27 PM Flag

    Is when i expect the meeting to occur with the FDA. I definitely feel this will be approved before June.

    Sentiment: Strong Buy

KERX
14.876-0.314(-2.07%)3:21 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.